---
title: "Jincheng Pharm: Subsidiary products are expected to be selected for the 11th batch of national centralized drug procurement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263100492.md"
description: "On October 28th, Jincheng Pharm announced that its wholly-owned subsidiary Beijing Jincheng Tail Pharmaceutical Co., Ltd. and its holding subsidiary Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd. participated in the bidding for the 11th batch of national centralized drug procurement organized by the National Organization for Drug Centralized Procurement and Use Joint Procurement Office. Jincheng Tail's Rebapamide tablets and Jincheng Jinsu's injectable Cefazolin Sodium are expected to be selected in this centralized procurement"
datetime: "2025-10-28T13:15:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263100492.md)
  - [en](https://longbridge.com/en/news/263100492.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263100492.md)
---

# Jincheng Pharm: Subsidiary products are expected to be selected for the 11th batch of national centralized drug procurement

On October 28th, Jincheng Pharm announced that its wholly-owned subsidiary Beijing Jincheng Taier Pharmaceutical Co., Ltd. and its holding subsidiary Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd. participated in the bidding for the 11th batch of national centralized drug procurement organized by the National Organization for Drug Centralized Procurement and Use Joint Procurement Office. Jincheng Taier's Rebapamide Tablets and Jincheng Jinsu's Cefazolin Sodium for Injection are expected to be selected in this centralized procurement

### Related Stocks

- [300233.CN](https://longbridge.com/en/quote/300233.CN.md)

## Related News & Research

- [China Resources Pharmaceutical Moves to Become Largest Shareholder in Lier Chemical](https://longbridge.com/en/news/294273054.md)
- [02:15 ETCellOrigin Unveils Two Novel Solid-Tumor Cell Therapy Candidates at ASCO 2026, Partners with Walvax for In Vivo CAR Clinical Trial](https://longbridge.com/en/news/294462606.md)
- [Shenzhen GTJA co-leads Changyu Pharma’s CNY 250 million Series D financing round](https://longbridge.com/en/news/294028268.md)
- [Thor Medical starts commercial production at AlphaOne isotope facility](https://longbridge.com/en/news/294456887.md)
- [Arcadis rejects WSP’s revised takeover proposal valuing shares at EUR 51.5](https://longbridge.com/en/news/294304061.md)